B3GNT5 is a novel marker correlated with malignant phenotype and poor outcome in pancreatic cancer

Wei Yao; Yihui Wang; Xin Zhang; Yuhe Lin

doi:10.1016/j.isci.2024.110889

B3GNT5 is a novel marker correlated with malignant phenotype and poor outcome in pancreatic cancer

iScience. 2024 Sep 5;27(10):110889. doi: 10.1016/j.isci.2024.110889. eCollection 2024 Oct 18.

Authors

Wei Yao¹, Yihui Wang¹, Xin Zhang¹, Yuhe Lin²

Affiliations

¹ Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang, P.R. China.
² Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, P.R. China.

Abstract

Pancreatic cancer (PC) is one of the most lethal malignancies and new therapeutic strategies are urgently needed. β1,3-N-acetylglucosaminyltransferase V (B3GNT5) may be a potential option for cancer treatment, but its role in PC remains unknown. In this study, we first demonstrated through bioinformatics analysis that B3GNT5 was high expression in PC and predicted poor prognosis. We further constructed B3GNT5 overexpression or knockdown cell lines by employing lentivirus packaging techniques and confirmed that B3GNT5 could promote tumor cell viability and autonomous growth using cultured cells and vivo xenograft models. In addition, we found that knockdown of B3GNT5 in PC cells inhibited cell migration, invasion, and angiogenesis, as well as stemness of cancer stem cells and enhanced chemotherapy sensitivity to gemcitabine. Mechanistically, overexpression of the transcription factor STAT5B in PC cells enhanced the transcriptional activity of the B3GNT5 promoter. Our work confirmed a tumor-promotive role of B3GNT5 in PC pathogenesis.

Keywords: Cancer; Cell biology; Molecular biology.